Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study.

ABSTRACT:

Objective

Dose optimization of TNF inhibitors in axial spondyloarthritis (axSpA) is attractive, but it is unclear for which patients this approach might be appropriate.

Methods

Seventy-one patients with axSpA, from six UK centres, were identified who had reduced their dose of TNF inhibitor after being considered to be stable responders. All completed a questionnaire concerning their approach to and experience of dose reduction. Data on patient characteristics, metrology and CRP were retrieved retrospectively from patient records.

Results

Over 2 years of observation, 60 (84.5%) remained (REM) on reduced-dose medication and 11 (15.5%) reverted (REV) to the original dose. The overall mean dose reduction was 39% for REM patients and 44% for REV patients. Both groups initi

SUBMITTER: Van Rossen L 

PROVIDER: S-EPMC7415263 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature